Erbstatin analog. Inhibitor of EGF receptor-associated tyrosine kinases.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in ethanol|
Preparing Stock Solutions
The following data is based on the product molecular weight 194.19. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.15 mL||25.75 mL||51.5 mL|
|5 mM||1.03 mL||5.15 mL||10.3 mL|
|10 mM||0.51 mL||2.57 mL||5.15 mL|
|50 mM||0.1 mL||0.51 mL||1.03 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Isshiki et al (1990) Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 260 198 PMID: 2298299
If you know of a relevant reference for Methyl 2,5-dihydroxycinnamate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Methyl 2,5-dihydroxycinnamate, supplier, EGFR, kinase, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, ErbB, Her, RTK, Receptor, Tyrosine, Kinases, RTKs, Methyl-25-dihydroxycinnamate, Erbstatin, analog, EGFR, EGFR, Tocris Bioscience
Citations for Methyl 2,5-dihydroxycinnamate
Citations are publications that use Tocris products.
Currently there are no citations for Methyl 2,5-dihydroxycinnamate. Do you know of a great paper that uses Methyl 2,5-dihydroxycinnamate from Tocris? If so please let us know.
Literature in this Area
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.